Rheumatology

                   

Data Demonstrate ORENCIA(R) (abatacept) Improves Health Related Quality of Life, Pain and Sleep ...

scouty.de
28-Oct-2008
        

Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA® (abatacept), compared to...

add comment
                   

Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With...

redorbit.com
27-Oct-2008
        

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX)...

add comment
                   

Nuvo Research Presents Positive Phase III Study Results for Pennsaid at Leading Rheumatology...

redorbit.com
27-Oct-2008
        

Posted on: Monday, 27 October 2008, 18:00 CDT MISSISSAUGA, ON, Oct. 27 /PRNewswire-FirstCall/ -- Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products...

add comment
                   

Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With ...

scouty.de
27-Oct-2008
        

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX)...

add comment

Nanocort demonstrates safety and good response in phase I/II trial for rheumatoid arthritis

news-medical.net
27-Oct-2008
        

Galapagos NV has announced that Nanocort has demonstrated safety as well as a faster and more pronounced decrease in rheumatoid arthritis disease symptoms compared to reference medication. These results were obtained in an...

add comment
                   

Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With...

wallstreet-online.de
27-Oct-2008
        

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX)...

add comment

Nanocort(R) Demonstrates Safety and Good Response in Phase I/II Trial

redorbit.com
27-Oct-2008
        

Results to be presented today at the 2008 American College of Rheumatology Annual Scientific Meeting in San Francisco, USA Galapagos NV (Euronext: GLPG) announces that Nanocort has demonstrated safety as well as a faster and...

add comment
                   

Rheumatoid Arthritis On The Rise Among American Women

medicalnewstoday.com
27-Oct-2008
        

Scientists presenting findings of their research at a conference in the United States at the weekend said they found evidence that after four decades of decline, rheumatoid arthritis was on the rise among American women.

add comment
                   

Traditional Cardiovascular Risk Factors Increase, Treatments Reduce Heart Attack Risk In People...

medicalnewstoday.com
27-Oct-2008
        

Age, sex and traditional risk factors - such as hypertension, diabetes, smoking, and body mass - are more important predictors of heart attack in patients with rheumatoid arthritis than the use of certain medications that have...

add comment
                   

Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With...

yahoo.com
27-Oct-2008
        

SAN FRANCISCO----Bristol-Myers Squibb Company today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis who had never received previous methotrexate treatment.

add comment